Spero gets ex-China rights to Innovent’s antibody therapy for up to $1.1B

PartnershipPositive

AI Analysis

Summary

Spero Therapeutics acquired exclusive ex-China rights to Innovent Biologics' antibody therapy with total deal value reaching up to $1.1 billion. The licensing agreement expands Spero's development pipeline in regions outside mainland China.

Importance:7/10

Sentiment:

0.60

licensing_dealantibody_therapychina_rightspartnership

Related Companies

$CHHE

Read the original article

Published by Seeking Alpha Healthcare on July 14, 2026 12:28 PM

Read Original